EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7–9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was inve...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Franceschi, Enrico, Stupp, Roger, van den Bent, Martin J., van Herpen, Carla, Laigle Donadey, Florence, Gorlia, Thierry, Hegi, Monika, Lhermitte, Benoit, Strauss, Lewis C., Allgeier, Anouk, Lacombe, Denis, Brandes, Alba A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2012
Gaiak:
Clinical Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3499012/
https://ncbi.nlm.nih.gov/pubmed/23090987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos256
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak